Status:
WITHDRAWN
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
Lead Sponsor:
University of Chicago
Conditions:
Oropharyngeal Cancer
HPV-Related Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Enrollment is only available to patients enrolled on the Optima II study (NCT03107182). The purpose of this trial is to compare rates of opioid use at completion of radiation for patients with Common...
Detailed Description
Enrollment is only available to patients enrolled on the Optima II study (NCT03107182). Primary objective: To compare rates of opioid requirement as a function of supportive care in patients experien...
Eligibility Criteria
Inclusion
- Enrollment to OPTIMA II trial (NCT03107182)
Exclusion
- Ineligible for enrollment to OPTIMA II trial (NCT03107182)
- Prior gabapentin therapy
- Creatinine clearance of \< 45 mL/minute
- Documented intolerance, allergy, or hypersensitivity to gabapentin
- Hemodialysis or peritoneal dialysis
Key Trial Info
Start Date :
January 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03423264
Start Date
January 22 2018
End Date
November 8 2022
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago Medical Center
Chicago, Illinois, United States, 60637